Novel and emerging agents have expanded the horizon for treatment of advanced gastric cancer. Molecular classification and targeted therapies make an individualized approach possible. This interactive video lecture addresses appropriate agent selection, strategies and sequences for designing an effective regimen, and management of treatment-related adverse events. Throughout the activity, a case study demonstrates key decision points in a patient-centered manner.
Interactive video lecture
After completing this activity, participants should be better able to:
- Summarize novel and emerging treatment options for advanced gastric cancer
- Identify recommended and emerging treatment strategies and sequences for gastric cancer
- Implement strategies to manage adverse events associated with novel treatments for advanced gastric cancer and improve patient outcomes and quality of life
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Kelley A. Rone, DNP, Mayo Clinic, Phoenix, Arizona
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until March 19, 2022. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was developed from a live program cosupported by educational grants from AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck & Co., Inc.; and Taiho Oncology, Inc.
This activity is supported by an educational grant from Merck & Co., Inc. and Taiho Oncology, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Ilson: advisory board: Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, IQVIA, Lilly, MacroGenics, Merck, Pieris Pharmaceuticals, Taiho Pharmaceutical.
Ms DiBenedetto has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: March 20, 2021
Expiration date: March 19, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 100320BTC-7E